HGS discontinues repifermin
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryHuman Genome Sciences ceases development of repifermin, the firm announces Feb. 2. The keratinocyte growth factor was not statistically different from placebo in a Phase II study in cancer therapy-induced mucositis. "No other clinical trials of repifermin are underway or planned in any indication"...
You may also be interested in...
Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.
FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.
Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.